Pharmacokinetic study of the interaction between itraconazole and nevirapine

European Journal of Clinical Pharmacology

Volumn 63, Issue 5, 2007, Pages 451-456

  Jaruratanasirikul, Sutep ^a   Sriwiriyajan, Somchai ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Antifungal agent; Antiretroviral drug; Itraconazole; Nevirapine; Pharmacokinetics

Indexed keywords

ITRACONAZOLE; NEVIRAPINE; SPORAL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; ITRACONAZOLE; MALE; NEVIRAPINE;

EID: 34147099619     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0280-x     Document Type: Article

References (19)

1. Gazzard B, on behalf of the BHIVA Writing Committee (2005) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 6 (Suppl 2):1-61
2. Varis T, Kivisto KT, Backman JT, Neuvonen PJ (2000) The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 68:487-494
3. Araki K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K (2004) Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 60:427-430
4. Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485
5. Piscitelli SC, Gallicano KD (2001) Interaction among drugs for HIV and opportunistic infections. N Engl J Med 344:984-996
6. Murphy RL, Montaner J (1996) Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 5:1183-1199
7. Loo TW, Clarke DM (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206:173-185
8. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ (2002) Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 19:1038-1045
9. Almond LM, Edirisnghe D, Dalton M, Bonington A, Back DJ, Khoo SH (2005) Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 78:132-142
10. Balayssac D, Authier N, Cayre A, Coudore F (2005) Does inhibition of P-glycoprotein lead to drug-drug interaction? Toxicol Lett 156:319-329
11. Lopez RM, Pou L, Gomez MR, Ruiz I, Monterde J (2001) Simple and rapid determination of nevirapine in human serum by reversephase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 751:371-376
12. Badcock NR (1990) Micro-scale method for itraconazole in plasma by reversed-phase high-performance liquid chromatography. J Chromatogr 525:478-483
13. Grant SM, Clissold SP (1989) Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 37:310-344
14. Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, Edwards DJ (1995) Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 58:617-624
15. Albengres E, Le Louet H, Tillement JP (1998) Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 18:83-97
16. Bottiger Y, Tybring G, Gotharson E, Bertilsson L (1997) Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 62:384-391
17. Kishimolo W, Takano J, Senda C, Ishiquro N, Sakai K, Iqarashi T (2000) Quantitative prediction of in vitro drug interaction between nevirapine and antifungal agents from in vitro data in rats. Biol Pharm Bull 23:1027-1032
18. Lamson M, Robinson P, Gigliotti M, Myers MW (1998) The pharmacokinetic interaction of nevirapine and ketoconazole. In: Abstracts of the 12th World AIDS Conference, Geneva, Switzerland, Abstract 12218, p 55
19. Cartledge ID, Midgely J, Gazzard BG (1997) Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 50:477-480